← Sites

703 (USA)

USA PI: Dr. Okafor activated KRI 0.2
Patients
19
Active (enrolled/consented)
0
Withdrawn
4
Serious AEs
0
Open QA findings
2
Aged data queries
0

Studies & contracts total budget 225500.00 USD

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II study completed contract executed 225500 USD

Patients first 19

RefStatusConsentedStudy
703-1042 completed 2013-03-02 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1076 completed 2013-10-25 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1086 completed 2012-09-02 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1096 withdrawn 2013-01-25 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1100 completed 2013-03-13 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1119 completed 2013-02-20 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1175 completed 2013-12-20 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1182 completed 2013-10-17 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1197 withdrawn 2013-06-16 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1210 completed 2013-03-16 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1258 completed 2012-07-20 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1279 withdrawn 2013-05-13 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1295 withdrawn 2013-11-21 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1299 completed 2012-09-12 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1335 completed 2014-03-17 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1379 completed 2013-09-22 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1396 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1403 completed 2012-12-12 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
703-1439 completed 2014-03-12 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.

Luna participants (0)

No participants at this site use Luna yet.

Safety 61 AEs · 0 serious

No serious adverse events at this site.

QA findings 2 open

open major Protocol deviation

PROTOCOL VIOLATION: PROTOCOL ENTRY CRITERIA NOT MET (subject 703-1175, 2013-12-31)

open major Protocol deviation

PROTOCOL VIOLATION: PROTOCOL VIOLATION (subject 703-1335, 2014-05-24)

Monitoring visits (0)

No visits recorded.

Payments (0)

No payments on file.